The DIXDC1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A2780 ovarian carcinoma cells in which DIXDC1 expression has been disrupted. This knockout model provides a heterogeneous pool of gene-edited cells, enabling loss-of-function studies without single-cell cloning. The polyclonal format preserves biological variability and is suitable for functional genomics, signaling analyses, and high-throughput screening in an epithelial ovarian cancer context.
The parental A2780 cell line was derived from an untreated patient with ovarian carcinoma and retains wild-type TP53 and BRCA1/2 alleles. Its cisplatin sensitivity and intact DNA damage response make it an ideal host for probing DIXDC1-regulated pathways relevant to therapeutic resistance. The adherent epithelial morphology facilitates standard imaging, proliferation, and migration assays.
DIXDC1 is a scaffold protein that enhances canonical Wnt/??-catenin signaling by binding DVL (DVL1/2/3) and AXIN (AXIN1/2), thereby inhibiting the ??-catenin destruction complex. This promotes ??-catenin stabilization and TCF/LEF-dependent transcription of targets including CCND1 and MYC. DIXDC1 also participates in non-canonical Wnt/PCP signaling via JNK and interacts with PI3K/AKT components. Upstream, WNT3A ligands activate FZD/LRP5/6 receptors to recruit DVL, positioning DIXDC1 as a key node.
In A2780 cells, DIXDC1 knockout attenuates Wnt-driven proliferation and migration, providing a platform to dissect its oncogenic roles in ovarian carcinoma. The model??s wild-type TP53 status allows independent analysis of DIXDC1 function, circumventing confounding p53 mutations. This system is particularly valuable for investigating mechanisms of cisplatin sensitivity and for evaluating Wnt pathway contributions to chemoresistance in a clinically relevant background.
Applications include TOPFlash/FOPFlash reporter assays for TCF/LEF activity, Western blotting for ??-catenin and DVL, qPCR for CCND1/MYC, immunofluorescence for ??-catenin localization, MTT proliferation and wound-healing migration assays, and cisplatin sensitivity testing. Co-immunoprecipitation can assess DIXDC1-DVL interactions. The polyclonal knockout pool is also suited for high-throughput chemical or RNAi screens to identify Wnt pathway modulators. For further details, contact Ascent Research.
